In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and convenience of anti-VEGF therapy.
Jay S. Duker, MD
Advertisement
Articles by Jay S. Duker, MD
Study aims to identify methodology for least amount of variation, greatest test-retest reliability
Advertisement
Latest Updated Articles
Parafoveal retinal vessel density assessment by OCTA in healthy eyesPublished: July 25th 2018 | Updated:
Advertisement
Advertisement
Trending on Modern Retina
1
AAO 2025: Ashkan Abbey on the outcomes of EYP-1901 for AMD and DME
2
AAO 2025: Inder Paul Singh, MD, shares his experience with the Academy Technician Training Platform
3
Retina roundup: October 13 to October 17
4
Empowerment through education: Q&A with Inder Paul Singh, MD
5
